Which has better valuation and earnings, KLRA or KRYS?

Krystal Biotech has higher revenue and earnings than Kailera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A N/A N/A Krystal Biotech $389.13M 28.20 $204.83M $7.48 49.77

Which has higher earnings & valuation, KLRA or CYTK?

Kailera Therapeutics has higher earnings, but lower revenue than Cytokinetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A N/A N/A Cytokinetics $88.04M 116.13 -$784.96M -$6.84 N/A

Is KLRA or CYTK more profitable?

Kailera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Cytokinetics -784.02% N/A -52.86%

Which has better valuation and earnings, NUVL or KLRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Kailera Therapeutics N/A N/A N/A N/A N/A

Is NUVL or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Kailera Therapeutics N/A N/A N/A

Which has stronger valuation and earnings, TGTX or KLRA?

TG Therapeutics has higher revenue and earnings than Kailera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 13.87 $447.18M $2.86 19.52 Kailera Therapeutics N/A N/A N/A N/A N/A

Which has preferable earnings and valuation, ABVX or KLRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Kailera Therapeutics N/A N/A N/A N/A N/A

Is ABVX or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Kailera Therapeutics N/A N/A N/A

Kailera Therapeutics (KLRA) Competitors

$20.83 0.00 (0.00%)

As of 06/26/2026 04:00 PM Eastern

Compare

KLRA vs. KRYS, CYTK, NUVL, TGTX, and ABVX

Should you buy Kailera Therapeutics stock or one of its competitors? MarketBeat compares Kailera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kailera Therapeutics include Krystal Biotech (KRYS), Cytokinetics (CYTK), Nuvalent (NUVL), TG Therapeutics (TGTX), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Kailera Therapeutics compare to Krystal Biotech?

Kailera Therapeutics (NASDAQ:KLRA) and Krystal Biotech (NASDAQ:KRYS) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

In the previous week, Krystal Biotech had 7 more articles in the media than Kailera Therapeutics. MarketBeat recorded 8 mentions for Krystal Biotech and 1 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 1.44 beat Krystal Biotech's score of 0.30 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kailera Therapeutics	Positive
Krystal Biotech	Neutral

Krystal Biotech has higher revenue and earnings than Kailera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
Krystal Biotech	$389.13M	28.20	$204.83M	$7.48	49.77

Kailera Therapeutics presently has a consensus target price of $42.75, indicating a potential upside of 105.23%. Krystal Biotech has a consensus target price of $340.56, indicating a potential downside of 8.51%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Kailera Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has a net margin of 53.92% compared to Kailera Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Kailera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Krystal Biotech	53.92%	19.25%	17.62%

86.3% of Krystal Biotech shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Krystal Biotech beats Kailera Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Kailera Therapeutics compare to Cytokinetics?

Kailera Therapeutics (NASDAQ:KLRA) and Cytokinetics (NASDAQ:CYTK) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Kailera Therapeutics has higher earnings, but lower revenue than Cytokinetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
Cytokinetics	$88.04M	116.13	-$784.96M	-$6.84	N/A

Kailera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Cytokinetics	-784.02%	N/A	-52.86%

Kailera Therapeutics presently has a consensus target price of $42.75, suggesting a potential upside of 105.23%. Cytokinetics has a consensus target price of $100.20, suggesting a potential upside of 21.95%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Kailera Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Cytokinetics had 6 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Cytokinetics and 1 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 1.44 beat Cytokinetics' score of 0.85 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kailera Therapeutics	Positive
Cytokinetics	Positive

Summary

Kailera Therapeutics beats Cytokinetics on 5 of the 9 factors compared between the two stocks.

How does Kailera Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Nuvalent had 3 more articles in the media than Kailera Therapeutics. MarketBeat recorded 4 mentions for Nuvalent and 1 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 1.44 beat Nuvalent's score of 0.72 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvalent	Positive
Kailera Therapeutics	Positive

97.3% of Nuvalent shares are held by institutional investors. 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nuvalent presently has a consensus price target of $127.73, indicating a potential upside of 3.41%. Kailera Therapeutics has a consensus price target of $42.75, indicating a potential upside of 105.23%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Kailera Therapeutics' return on equity of 0.00% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Kailera Therapeutics	N/A	N/A	N/A

Summary

Kailera Therapeutics beats Nuvalent on 7 of the 10 factors compared between the two stocks.

How does Kailera Therapeutics compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

TG Therapeutics has higher revenue and earnings than Kailera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.87	$447.18M	$2.86	19.52
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, TG Therapeutics and TG Therapeutics both had 1 articles in the media. TG Therapeutics' average media sentiment score of 1.87 beat Kailera Therapeutics' score of 1.44 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TG Therapeutics	Very Positive
Kailera Therapeutics	Positive

TG Therapeutics presently has a consensus price target of $58.60, suggesting a potential upside of 4.96%. Kailera Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 105.23%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

58.6% of TG Therapeutics shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TG Therapeutics has a net margin of 65.95% compared to Kailera Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Kailera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Kailera Therapeutics	N/A	N/A	N/A

Summary

TG Therapeutics beats Kailera Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Kailera Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Abivax currently has a consensus target price of $130.08, indicating a potential upside of 33.41%. Kailera Therapeutics has a consensus target price of $42.75, indicating a potential upside of 105.23%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Abivax had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 3 mentions for Abivax and 1 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 1.44 beat Abivax's score of 0.84 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Abivax	Positive
Kailera Therapeutics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

47.9% of Abivax shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kailera Therapeutics' return on equity of 0.00% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Kailera Therapeutics	N/A	N/A	N/A

Summary

Kailera Therapeutics beats Abivax on 6 of the 9 factors compared between the two stocks.

Get Kailera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRA vs. The Competition

Export

Metric	Kailera Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$2.70B	$982.31M	$4.35B	$12.17B
Dividend Yield	N/A	4.84%	12.97%	6.11%
P/E Ratio	N/A	1.50	22.01	24.17
Price / Sales	N/A	118.69	160.43	102.83
Price / Cash	N/A	20.06	36.62	36.93
Price / Book	N/A	8.05	13.62	6.38
Net Income	N/A	-$3.83M	$113.19M	$337.00M
7 Day Performance	-8.96%	0.61%	-0.99%	-0.20%
1 Month Performance	-9.40%	-0.72%	-3.43%	-1.40%
1 Year Performance	N/A	52.18%	11.94%	27.76%

Kailera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRA Kailera Therapeutics	4.9603 of 5 stars	$20.83 flat	$42.75 +105.2%	N/A	$2.70B	N/A	N/A	145	Positive News Gap Down High Trading Volume
KRYS Krystal Biotech	2.2427 of 5 stars	$348.06 flat	$340.56 -2.2%	+168.0%	$10.26B	$389.13M	46.53	210	Insider Trade Gap Down High Trading Volume
CYTK Cytokinetics	3.0414 of 5 stars	$78.78 flat	$99.30 +26.0%	+147.8%	$9.80B	$88.04M	N/A	250
NUVL Nuvalent	2.4461 of 5 stars	$123.43 flat	$131.15 +6.3%	+55.0%	$9.75B	N/A	N/A	40	Positive News Short Interest Decrease
TGTX TG Therapeutics	2.9037 of 5 stars	$53.22 flat	$52.50 -1.4%	+52.0%	$8.15B	$616.29M	18.61	290	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRA) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kailera Therapeutics (KLRA) Competitors

KLRA vs. KRYS, CYTK, NUVL, TGTX, and ABVX

How does Kailera Therapeutics compare to Krystal Biotech?

Summary

How does Kailera Therapeutics compare to Cytokinetics?

Summary

How does Kailera Therapeutics compare to Nuvalent?

Summary

How does Kailera Therapeutics compare to TG Therapeutics?

Summary

How does Kailera Therapeutics compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kailera Therapeutics (KLRA) Competitors

KLRA vs. KRYS, CYTK, NUVL, TGTX, and ABVX

How does Kailera Therapeutics compare to Krystal Biotech?

Does the media prefer KLRA or KRYS?

Which has better valuation and earnings, KLRA or KRYS?

Do analysts rate KLRA or KRYS?

Is KLRA or KRYS more profitable?

Do insiders & institutionals believe in KLRA or KRYS?

Summary

How does Kailera Therapeutics compare to Cytokinetics?

Which has higher earnings & valuation, KLRA or CYTK?

Is KLRA or CYTK more profitable?

Do analysts prefer KLRA or CYTK?

Does the media prefer KLRA or CYTK?

Summary

How does Kailera Therapeutics compare to Nuvalent?

Does the media prefer NUVL or KLRA?

Do institutionals and insiders have more ownership in NUVL or KLRA?

Do analysts rate NUVL or KLRA?

Which has better valuation and earnings, NUVL or KLRA?

Is NUVL or KLRA more profitable?

Summary

How does Kailera Therapeutics compare to TG Therapeutics?

Which has stronger valuation and earnings, TGTX or KLRA?

Does the media refer more to TGTX or KLRA?

Do analysts rate TGTX or KLRA?

Do institutionals & insiders have more ownership in TGTX or KLRA?

Is TGTX or KLRA more profitable?

Summary

How does Kailera Therapeutics compare to Abivax?

Do analysts rate ABVX or KLRA?

Does the media favor ABVX or KLRA?

Which has preferable earnings and valuation, ABVX or KLRA?

Do institutionals & insiders hold more shares of ABVX or KLRA?

Is ABVX or KLRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools